Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04900038 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT04900038 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 85 participants.
The verdict
NCT04900038, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1. The participants were randomized to one of the three doses of blinded GSK3640254 (100, 150, or 200 milligrams \[mgs\]) or a reference arm of blinded 3TC-each in combination with open label DTG.
Interventions
- DRUG Dolutegravir
- DRUG GSK3640254
- DRUG Lamivudine capsules
- DRUG Lamivudine tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2021-08-18 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04900038
The ClinicalTrials.gov registry entry for NCT04900038 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dolutegravir is the first listed.
NCT04900038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04900038 about?
NCT04900038 is a clinical study titled "A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults". The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1. The participants were randomized to one of the three doses of blinded GSK3640254 (100, 150, or 200 mil...
What is the current status of trial NCT04900038?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2021-08-18. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT04900038?
The interventions under investigation include: Dolutegravir (DRUG), GSK3640254 (DRUG), Lamivudine capsules (DRUG), Lamivudine tablets (DRUG).
Who is sponsoring clinical trial NCT04900038?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.